Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2930)	8/10/2005 12:11:33 PM
From: Biomaven	Respond to of 12215

if investors are overjoyed that the company has more money to apply to its great pipeline? I think that's giving said "investors" too much credit. I suspect it's more along the lines of "We asked the underwriters for $10m worth of shares because we have all this money floating around in our fund, but they only gave us $6m worth. So seeing we already decided to make the investment, we went ahead and bought the other $4m in the aftermarket anyhow." Peter

To: scaram(o)uche who wrote (2930)	8/10/2005 5:32:51 PM
From: tom pope	Respond to of 12215

Thanks for the clarification. I thought the Peter principle was - never buy a biotech with a Florida zip code - so I was totally confused.

To: scaram(o)uche who wrote (2930)	8/10/2005 6:46:54 PM
From: tuck	Read Replies (3) \| Respond to of 12215

Off Topic Science question for ya, Rick (others who feel qualified may chip in). You've worked with antibodies, so maybe you can help. Prealbumin or transthyretin (TTR) has two binding sites. These are not on the n-terminal. They're in the binding channel that runs down the center of the tetramer. Suppose you've got a serum sample you want to assay for a fragment of TTR that has had its n-terminal lopped off (i.e. the fragment you want has the binding site). Could one design an antibody that would allow an immunoassy (specifically, an ELISA) to find only that fragment, and not whole TTR or other isoforms thereof? I'd guess cross-reactivity with these other forms is going to doom an immunoassay approach. TIA for any help, and Cheers, Tuck, who is off to climb and drink beer, in that order.